Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
Biomedical Technology
/ economics
Choice Behavior
Costs and Cost Analysis
Decision Making
Decision Support Techniques
Europe
Health Services Research
/ organization & administration
Humans
Patient Preference
Pilot Projects
Reimbursement Mechanisms
Research Design
Surveys and Questionnaires
Technology Assessment, Biomedical
/ methods
European regulatory
benefit-risk assessment
health preferences
health technology assessment
marketing authorization
preference research
pricing
quantitative preference data
reimbursement
stakeholder preferences
Journal
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
07
05
2019
revised:
07
11
2019
accepted:
27
11
2019
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
23
9
2020
Statut:
ppublish
Résumé
This study examines European decision makers' consideration and use of quantitative preference data. The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement, or pricing decisions. Use was defined as: agency guidance on preference data use, sponsor submission of preference data, or decision-maker collection of preference data. The data could be collected from any stakeholder using any method that generated quantitative estimates of preferences. Data were collected through: (1) documentary evidence identified through a literature and regulatory websites review, and via key opinion leader outreach; and (2) a survey of staff working for agencies that support or make healthcare technology decisions. Preference data utilization was identified in 22 countries and at a European level. The most prevalent use (19 countries) was citizen preferences, collected using time-trade off or standard gamble methods to inform health state utility estimation. Preference data was also used to: (1) value other impact on patients, (2) incorporate non-health factors into reimbursement decisions, and (3) estimate opportunity cost. Pilot projects were identified (6 countries and at a European level), with a focus on multi-criteria decision analysis methods and choice-based methods to elicit patient preferences. While quantitative preference data support reimbursement and pricing decisions in most European countries, there was no utilization evidence in European-level marketing authorization decisions. While there are commonalities, a diversity of usage was identified between jurisdictions. Pilots suggest the potential for greater use of preference data, and for alignment between decision makers.
Identifiants
pubmed: 32762984
pii: S1098-3015(20)30091-7
doi: 10.1016/j.jval.2019.11.009
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-841Subventions
Organisme : AHRQ HHS
ID : K12 HS026370
Pays : United States
Informations de copyright
Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.